UCB SA (UCB.BR) News| Reuters.com
Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

63.67EUR
4:00am EDT
Change (% chg)

€1.41 (+2.26%)
Prev Close
€62.26
Open
€63.51
Day's High
€63.88
Day's Low
€63.40
Volume
42,054
Avg. Vol
393,374
52-wk High
€86.05
52-wk Low
€61.60

Select another date:

Fri, Jun 10 2016

BRIEF-UCB's bimekizumab demonstrates positive results

* Says its bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis Source text: http://bit.ly/1sy2B6M Further company coverage: (Gdynia Newsroom)

BRIEF-UCB announces new clinical trial data on lacosamide

* Says new clinical trial data, presented at the second Congress of the European Academy of Neurology, showed non-inferiority of lacosamide (VIMPAT) monotherapy compared with controlled-release carbamazepine among patients with newly or recently diagnosed focal epilepsy Source text: http://bit.ly/1slGMaJ Further company coverage: (Gdynia Newsroom)

UCB faces U.S. patent challenge for epilepsy drug

BRUSSELS The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals.

UCB faces U.S. patent challenge for epilepsy drug

BRUSSELS The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals.

UPDATE 1-UCB faces U.S. patent challenge for epilepsy drug

* U.S. court verdict on Vimpat likely in June (Adds shares, legal battle, analyst comment)

UCB faces U.S. patent challenge for epilepsy drug

May 24 The U.S. Patent and Trademark Office (PTO) has begun a trial into whether Belgian pharmaceutical company UCB's patent for an epilepsy drug is valid, said a generic drug company that is challenging UCB's claim.

BRIEF-UCB Q1 revenue rises to 991 million euros

* Q1 revenue 991 million euros versus 895 million euros year ago

BRIEF-UCB announces results from study of Cimzia and Humira

* Announces results from first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients

BRIEF-UCB posts FY REBIT ahead of Reuters poll

* FY revenue and net sales increased driven by product growth: Cimzia, Vimpat, Neupro and Keppra combined reached net sales of 2.76 billion euros ($3.05 billion) (+29 pct); representing 77 pct of net sales

UCB forecasts earnings growth after 2015 beat

BRUSSELS, Feb 26 Belgian pharmaceutical group UCB forecast further expansion of revenue and profit this year after its three newer drugs drove earnings by more than expected in 2016.

Select another date: